Valeant Pharmaceuticals Intl Inc (NYSE:VRX), plans to take a buyout offer for Allergan directly to its shareholders this week, as the Botox maker continues to rebuff its proposals that have risen as high as $53 billion. Valeant Pharmaceuticals Intl Inc (NYSE:VRX), net profit margin is -13.10% and weekly performance is -5.32%. On last trading day company shares ended up $118.87. Analysts mean target price for the company is $52.38. Valeant Pharmaceuticals Intl Inc (NYSE:VRX), distance from 50-day simple moving average (SMA50) is -7.35%.
Analysts at Maxim Group started coverage on shares of Bio-Path Holdings Inc (NASDAQ:BPTH), in a research report issued to clients and investors on Monday. The firm set a “buy” rating and a $5.00 price target on the stock. Maxim Group’s price target would indicate a potential upside of 83.82% from the company’s current price. Bio-Path Holdings Inc (NASDAQ:BPTH), fell 1.76% in last trading session and ended the day on $3.34. BPTH, return on assets is -37.30%. Bio-Path Holdings Inc(NASDAQ:BPTH), quarterly performance is 4.37%.
Alkermes Plc (NASDAQ:ALKS), announced the presentation of data from its phase 3 clinical trial of aripiprazole lauroxil, an investigational drug candidate in development for schizophrenia, at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Hollywood, Fla. In the pivotal study, both doses of aripiprazole lauroxil tested, 441 mg and 882 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in Positive and Negative Syndrome Scale (PANSS) scores, met all secondary endpoints and demonstrated significant improvements in schizophrenia symptoms versus placebo. Alkermes Plc (NASDAQ:ALKS), shares moved down 0.31% in last trading session and was closed at $47.00, while trading in range of $46.80 – 47.72. Alkermes Plc (NASDAQ:ALKS), year to date (YTD) performance is 15.59%.
On May 29, 2014, Adamis Pharmaceuticals Corp (NASDAQ:ADMP), has submitted a New Drug Application or NDA to the U.S. Food and Drug Administration for its epinephrine pre-filled single dose syringe or PFS product. Particularly, the EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg Pre-filled single dose syringe) is designed for the emergency treatment of allergic reactions (Type I), including anaphylaxis. Adamis Pharmaceuticals Corp (NASDAQ:ADMP), ended the last trading day at $5.15. Company weekly volatility is calculated as 5.53% and price to cash ratio as 11.47. Adamis Pharmaceuticals Corp (NASDAQ:ADMP), showed a negative weekly performance of 3.20%.
Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), was downgraded by TheStreet from a “hold” rating to a “sell” rating in a research note issued on Tuesday. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), weekly performance is 9.92%. On last trading day company shares ended up $1.09. Analysts mean target price for the company is $75. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), distance from 50-day simple moving average (SMA50) is -10.77%.